Literature DB >> 26585488

MiR-661 inhibits glioma cell proliferation, migration and invasion by targeting hTERT.

Zhen Li1, Yun-hui Liu2, Hong-yu Diao2, Jun Ma3, Yi-long Yao2.   

Abstract

In this study, we analyzed the functional role of miR-661 in glioma cell proliferation, migration and invasion. We found that overexpression of miR-661 obviously suppressed the proliferation, migration and invasion of glioma cells. MiRNA target prediction algorithms implied that hTERT is a candidate target gene for miR-661. A fluorescent reporter assay confirmed that miR-661 could lead to hTERT gene silencing by recognizing and specifically binding to the predicted site of the hTERT mRNA 3' untranslated region (3'UTR) specifically. Furthermore, hTERT knockdown significantly decreased the growth and viability of glioma cells. These results indicate that miR-661 can inhibit glioma cell proliferation, migration and invasion by targeting hTERT.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell growth; Cell invasion; Glioma; MiR-661; hTERT

Mesh:

Substances:

Year:  2015        PMID: 26585488     DOI: 10.1016/j.bbrc.2015.11.046

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  CircPDE7B/miR-661 axis accelerates the progression of human keloid fibroblasts by upregulating fibroblast growth factor 2 (FGF2).

Authors:  Fenglian Wu; Hongbin He; Yanxin Chen; Donglai Zhu; Tao Jiang; Jiaxin Wang
Journal:  Mol Cell Biochem       Date:  2022-01-25       Impact factor: 3.396

2.  Hsa_circ_0103232 promotes melanoma cells proliferation and invasion via targeting miR-661/RAB3D.

Authors:  Xing Lin; Liang Zhong; Nian Wang; Xuan Chu; Beizhong Liu
Journal:  Cell Cycle       Date:  2022-05-13       Impact factor: 5.173

3.  EGR1-Mediated Transcription of lncRNA-HNF1A-AS1 Promotes Cell-Cycle Progression in Gastric Cancer.

Authors:  Hai-Ting Liu; Sen Liu; Lei Liu; Ran-Ran Ma; Peng Gao
Journal:  Cancer Res       Date:  2018-09-05       Impact factor: 12.701

4.  MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer.

Authors:  Feiye Liu; Yanjun Cai; Xiaoxiang Rong; Jinzhang Chen; Dayong Zheng; Lu Chen; Junyi Zhang; Rongcheng Luo; Peng Zhao; Jian Ruan
Journal:  Mol Cancer       Date:  2017-07-17       Impact factor: 27.401

5.  Circular RNA hsa-circ-0012129 Promotes Cell Proliferation and Invasion in 30 Cases of Human Glioma and Human Glioma Cell Lines U373, A172, and SHG44, by Targeting MicroRNA-661 (miR-661).

Authors:  Gang Xie
Journal:  Med Sci Monit       Date:  2018-04-24

6.  Putative biomarkers of malignant transformation of sinonasal inverted papilloma into squamous cell carcinoma.

Authors:  Zheng Yang; Yang Zhang; Xiangdong Wang; Junwei Huang; Wei Guo; Peng Wei; Guojun Li; Ziqiao Wang; Zhigang Huang; Luo Zhang
Journal:  J Int Med Res       Date:  2019-04-16       Impact factor: 1.671

Review 7.  Diverse regulatory manners of human telomerase reverse transcriptase.

Authors:  Meng-Meng Jie; Xing Chang; Shuo Zeng; Cheng Liu; Guo-Bin Liao; Ya-Ran Wu; Chun-Hua Liu; Chang-Jiang Hu; Shi-Ming Yang; Xin-Zhe Li
Journal:  Cell Commun Signal       Date:  2019-06-11       Impact factor: 5.712

8.  MicroRNA-661 modulates redox and metabolic homeostasis in colon cancer.

Authors:  Marta Gómez de Cedrón; Rebeca Acín Pérez; Ruth Sánchez-Martínez; Susana Molina; Jesús Herranz; Jaime Feliu; Guillermo Reglero; Jose Antonio Enríquez; Ana Ramírez de Molina
Journal:  Mol Oncol       Date:  2017-11-06       Impact factor: 6.603

Review 9.  MicroRNA Regulation of Telomerase Reverse Transcriptase (TERT): Micro Machines Pull Strings of Papier-Mâché Puppets.

Authors:  Ammad Ahmad Farooqi; Qaisar Mansoor; Nada Alaaeddine; Baojun Xu
Journal:  Int J Mol Sci       Date:  2018-04-01       Impact factor: 5.923

10.  Circular RNA expression and association with the clinicopathological characteristics in papillary thyroid carcinoma.

Authors:  Dan Guo; Fangyuan Li; Xiaoxiao Zhao; Bo Long; Sumei Zhang; Anqi Wang; Dingyan Cao; Jian Sun; Binglu Li
Journal:  Oncol Rep       Date:  2020-05-27       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.